|
| NLR低值组 | NLR高值组 | P值 |
性别,n (%) | 男 | 30 (85.7) | 28 (80.0) | 0.526 |
| 女 | 5 (14.3) | 7 (20.0) |
|
年龄,n (%),岁 | >60 | 14 (40.0) | 17 (48.6) | 0.808 |
| <60 | 21 (60.0) | 18 (51.4) |
|
乙肝,n (%) | yes | 30 (85.7) | 29 (82.9) | 0.743 |
| no | 5 (14.3) | 6 (17.1) |
|
肿瘤数目,n (%) | <2 | 8 (22.9) | 3 (8.6) | 0.188 |
| ≥2 | 27 (77.1) | 32 (91.4) |
|
AFP,n (%),ng/ml | >400 | 6 (17.1) | 9 (25.7) | 0.382 |
| ≤400 | 29 (82.9) | 26 (74.3) |
|
BCLC分期,n (%) | B | 25 (71.4) | 18 (51.4) | 0.086 |
| C | 10 (28.6) | 17 (48.6) |
|
转移,n (%) | 是 | 4 (11.4) | 6 (17.1) | 0.734 |
| 否 | 31 (88.6) | 29 (82.9) |
|
| 肺 | 2 (5.7) | 4 (11.4) |
|
| 淋巴结 | 2 (5.7) | 3 (8.6) |
|
治疗前方案,n (%) | TACE | 10 (28.6) | 15 (42.9) | 0.811 |
| 手术 | 9 (25.7) | 7 (20.0) |
|
| 放射疗法 | 2 (5.7) | 2 (5.7) |
|
| 射频消融 | 3 (8.6) | 3 (8.6) |
|
| 手术 + TACE | 16 (45.7) | 13 (37.1) |
|
靶向治疗,n (%) | 瑞戈非尼 | 12 (34.3) | 8 (22.9) | 0.175 |
| 索拉非尼 | 19 (54.3) | 17 (48.6) |
|
| 仑伐替尼 | 4 (11.4) | 10 (28.6) |
|